About Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license

CHRS Key Statistics

CHRS Price Performance

Coherus Oncology, Inc. stock has returned +0.00% over the past day, +4.14% over the past week, -12.44% over the past month, and +3.53% over the past three months. The stock trades between a 52-week low of $0.71 and a high of $2.62.

CHRS Financial Fundamentals

Coherus Oncology, Inc. reports a return on equity (ROE) of -29386.00%, operating margin of -201.91%, profit margin of -22433.59%, and revenue growth of -7254.00%. The debt-to-equity ratio is 0.62. Current ratio stands at 1.24.

CHRS Earnings

Coherus Oncology, Inc.'s next earnings report is expected on 2026-03-09 (4 days away). The company has a +0.25% earnings beat rate with an average surprise of -42.20%. Earnings consistency is rated as "low".

CHRS Ownership

Institutional investors hold approximately +0.35% of CHRS shares across 10 institutions. Insider ownership is +0.15%. Insider sentiment is "neutral".

CHRS Short Interest

CHRS has a short interest of +25.44% of float with a short ratio (days to cover) of 8.5.

CHRS AI Analysis Signal

iGotFomo's AI-powered signal engine rates CHRS as "LEAN SELL" with LOW confidence (score: 28/100). 3 signals are bullish, 7 are bearish, and 3 are neutral.